A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507
| Status: | Not yet recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/17/2018 |
| Start Date: | December 1, 2018 |
| End Date: | December 1, 2019 |
| Contact: | Sun Pharma Advanced Research Company Limited |
| Email: | clinical.trials@sparcmail.com |
| Phone: | +9122 66455645 |
A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 in Subjects With Cancer
An open label study to determine the efficacy and safety of SPARC1507
Subjects with advanced Biliary tract carcinoma meeting the eligibility criteria will be
randomized in this study.
randomized in this study.
Inclusion Criteria:
- Evidence of advanced/metastatic biliary tract cancer
- Male or female ≥ 18 years old
- Participants must have measurable disease according to RECIST
- ECOG performance status ≤ 1
Exclusion Criteria:
- Known hypersensitivity to trial treatments, or their excipients
- Prior history of treatment with any taxane therapy
- Cardiovascular disorders as per Investigator's discretion
- The subject has received radiation therapy
We found this trial at
1
site
